X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABI-009 (Nab-sirolimus) is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Lead Product(s): Nab-sirolimus,Sotorasib,Adagrasib
Therapeutic Area: Oncology Product Name: ABI-009
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study of Adagrasib (MRTX849), and jointly with Aadi, will oversee and share the cost of the study.
Lead Product(s): Adagrasib,Nab-sirolimus
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2022
Details:
The company intends to use net proceeds from the financing to fund research and development of Nab-sirolimus and additional clinical opportunities with FYARRO and for working capital and general corporate purposes.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avoro Capital
Deal Size: $72.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 22, 2022
Details:
Nab-sirolimus is an albumin-bound mTOR inhibitor approved by the U.S. Food and Drug Administration (FDA) as FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Partners will collect and analyze clinical and molecular data to determine which patients may be eligible to participate in Aadi’s PRECISION 1 clinical trial for ABI-009. The goals are to increase patient match rate, reduce screen failure rate and increase speed of enrollment.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: ABI-009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 09, 2022
Details:
Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors.
Lead Product(s): Nab-Sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Lead Product(s): Nab-Sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
nab-Sirolimus (ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors.
Lead Product(s): Nab-Sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
The combined, publicly traded company will focus on the advancement, expansion and commercialization of Aadi’s clinical stage pipeline, including Aadi’s lead program for its nanoparticle albumin-bound mTOR inhibitor, FYARRO™, an mTOR inhibitor bound to human albumin.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aerpio Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 26, 2021
Details:
Proceeds from the PIPE financing are expected to be used for the commercialization of FYARRO in advanced malignant PEComa, a planned tumor-agnostic registrational trial in solid tumors harboring inactivating alterations in the mTOR pathway genes TSC1 and TSC2.
Lead Product(s): Nab-sirolimus
Therapeutic Area: Oncology Product Name: Fyarro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acuta Capital Partners
Deal Size: $155.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
